Nelson N. Stone, MD

Icahn School of Medicine at Mount Sinai

New York, New York

Nelson N. Stone, MD, is Professor of Urology, Radiation Oncology, and Oncological Sciences at the Icahn School of Medicine at Mount Sinai and chief medical officer at Viomerse, Inc.

Dr. Stone earned his medical degree from the University of Maryland in 1979. He completed a Residency in General Surgery in 1981 at the University of Maryland, followed by a Residency in Urology at the University of Maryland. He then completed a Fellowship in Urologic Oncology at Memorial Sloan-Kettering Cancer Center and a Research Fellowship in Biochemical Endocrinology at Rockefeller University in 1986. He was Chief of Urology at Elmhurst Hospital Queens from 1986-1996.

Dr. Stone has founded several medical companies and serves on the editorial board of many scientific journals. He is a member of many professional societies, including the Prostate Conditions Education Council, the Society for Minimally Invasive Therapy, the New York State Urological Society, the American Association of Clinical Urologists, and the American Urologic Association. Dr. Stone has participated in approximately 25 research studies on prostate cancer and has authored more than 500 articles, abstracts, and book chapters, primarily on prostate cancer. He invented the real-time technique for prostate brachytherapy in 1990 and has trained more than 5,000 physicians worldwide through his company ProSeed. His most recent company, Viomerse, creates synthetic body parts (phantoms) for surgical training and has recently released an extended reality remote training platform.

Talks by Nelson N. Stone, MD

3DBiopsy™: Transperineal Mapping Biopsy in 2019

Posted by Nelson N. Stone, MD | Jun 2019

Nelson N. Stone, MD, discusses the need for adequate and accurate prostate cancer identification techniques, especially when selecting patients for active surveillance. He then reviews an emerging transperineal prostate mapping biopsy system that could be an improved tool for fusion biopsy, replace current transrectal biopsy devices, and better detect and localize lesions.

Long-term Morbidity of ADT and Radiation Therapy

Posted by Nelson N. Stone, MD | Jun 2019

Nelson N. Stone, MD, discusses long-term data about extended neoadjuvant hormone therapy following radiation therapy for high-risk prostate cancer patients. He observes the morbidity, mortality, and testosterone recovery rates of extended hormone therapy, especially in patients treated with hormone therapy for over 6 months.

Long-Term Erectile Dysfunction and Urinary Morbidity Following Brachytherapy

Posted by Nelson N. Stone, MD | Jul 2018

Nelson N. Stone, MD, discusses changes in urinary symptoms and erectile function, as measured by the International Prostate Symptom Score (IPPS), at 10 and 15 years following prostate brachytherapy. Subsequently, he advises clinicians on best practices in seed implantation and long-term management to optimize cancer control and minimize adverse symptoms.

Should MRI Be Used to Monitor for AS? Con Argument

Posted by Nelson N. Stone, MD | Jul 2018

Nelson N. Stone, MD, argues that MRI’s limitations make it insufficient for evaluating and managing prostate cancer patients under consideration for active surveillance (AS) or targeted focal therapy (TFT). Instead, urologists should consider technology like the under-development 3DBiopsy™ system, with a transperineal needle along with mapping software. This approach can detect the precise location of lesions and create a roadmap for treatment planning.

3DBiopsy™ Transperineal Mapping Biopsy

Posted by Nelson N. Stone, MD | Jul 2018

Nelson N. Stone, MD, Founder and CEO/President of 3DBiopsy™, discusses how his comprehensive system aides in accurately identifying Gleason scores and guiding focal therapy. He and 3DBiopsy™ co-founders, E. David Crawford, MD, and M. Scott Lucia, MD, perform a demonstration of the system’s needle, actuator, pathology carrier, and 3D mapping software.